J&J Expects Medical Devices Sales Boost from Cardiovascular -- Market Talk

Dow Jones

Jul 17, 2025

1327 ET - Johnson & Johnson expects medical technology sales to continue improving in the rest of the year, in part due to strong performance for its cardiovascular segment in its latest quarter, CEO Joaquin Duato says during a call with analysts. Operational sales of the segment were up 22%, driven by particularly strong growth for electrophysiology products and Abiomed, its subsidiary that manufactures cardiovascular medical implant devices, the company says. "Cardiovascular has some of the largest unmet needs in health care, and is one of the fastest-growing spaces in medtech," Duato says.(kelly.cloonan@wsj.com)

(END) Dow Jones Newswires

July 16, 2025 13:27 ET (17:27 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2552127212"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2552127212\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2552127212?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-17 01:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2552127212","market":"nz","top_or_hot":-1,"title":"J&J Expects Medical Devices Sales Boost from Cardiovascular -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1327 ET - Johnson &amp; Johnson expects medical technology sales to continue improving in the rest of the year, in part due to strong performance for its cardiovascular segment in its latest quarter, CEO Joaquin Duato says during a call with analysts. Operational sales of the segment were up 22%, driven by particularly strong growth for electrophysiology products and <a href=\"https://laohu8.com/S/ABMD\">Abiomed</a>, its subsidiary that manufactures cardiovascular medical implant devices, the company says. \"<a href=\"https://laohu8.com/S/CSII\">Cardiovascular</a> has some of the largest unmet needs in health care, and is one of the fastest-growing spaces in medtech,\" Duato says.(kelly.cloonan@wsj.com) \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 16, 2025 13:27 ET (17:27 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>J&J Expects Medical Devices Sales Boost from Cardiovascular -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJ&J Expects Medical Devices Sales Boost from Cardiovascular -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-07-17 01:27</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1327 ET - Johnson &amp; Johnson expects medical technology sales to continue improving in the rest of the year, in part due to strong performance for its cardiovascular segment in its latest quarter, CEO Joaquin Duato says during a call with analysts. Operational sales of the segment were up 22%, driven by particularly strong growth for electrophysiology products and <a href=\"https://laohu8.com/S/ABMD\">Abiomed</a>, its subsidiary that manufactures cardiovascular medical implant devices, the company says. \"<a href=\"https://laohu8.com/S/CSII\">Cardiovascular</a> has some of the largest unmet needs in health care, and is one of the fastest-growing spaces in medtech,\" Duato says.(kelly.cloonan@wsj.com) \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 16, 2025 13:27 ET (17:27 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CSII","symbol_name":"Cardiovascular Systems","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2552127212","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2552127212","pubTimestamp":1752686820,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"1327 ET - Johnson & Johnson expects medical technology sales to continue improving in the rest of the year, in part due to strong performance for its cardiovascular segment in its latest quarter, CEO Joaquin Duato says during a call with analysts. Operational sales of the segment were up 22%, driven by particularly strong growth for electrophysiology products and Abiomed, its subsidiary that manufactures cardiovascular medical implant devices, the company says. \"Cardiovascular has some of the largest unmet needs in health care, and is one of the fastest-growing spaces in medtech,\" Duato says.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"CSII":"Cardiovascular Systems","JNJ":"强生"},"translate_title":"强生预计心血管医疗器械销售将提振——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"JNJ":0.9,"CSII":1},"content_text":"1327 ET - Johnson & Johnson expects medical technology sales to continue improving in the rest of the year, in part due to strong performance for its cardiovascular segment in its latest quarter, CEO Joaquin Duato says during a call with analysts. Operational sales of the segment were up 22%, driven by particularly strong growth for electrophysiology products and Abiomed, its subsidiary that manufactures cardiovascular medical implant devices, the company says. \"Cardiovascular has some of the largest unmet needs in health care, and is one of the fastest-growing spaces in medtech,\" Duato says.(kelly.cloonan@wsj.com) \n\n\n  (END) Dow Jones Newswires\n\n\n  July 16, 2025 13:27 ET (17:27 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}